Thrivent Financial for Lutherans Lowers Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Thrivent Financial for Lutherans lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 98.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,423 shares of the medical research company's stock after selling 327,239 shares during the period. Thrivent Financial for Lutherans' holdings in Charles River Laboratories International were worth $1,001,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also modified their holdings of the company. Wellington Management Group LLP increased its stake in shares of Charles River Laboratories International by 135,927.9% in the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock valued at $736,819,000 after purchasing an additional 3,738,018 shares in the last quarter. State Street Corp increased its holdings in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock worth $419,601,000 after acquiring an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after acquiring an additional 47,221 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Charles River Laboratories International by 7.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 552,975 shares of the medical research company's stock worth $102,079,000 after purchasing an additional 37,753 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock valued at $95,086,000 after buying an additional 85,759 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Remove Ads

Insider Activity at Charles River Laboratories International

In other news, COO Birgit Girshick bought 1,514 shares of the business's stock in a transaction dated Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares of the company's stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Down 2.9 %

Shares of NYSE:CRL traded down $4.03 during trading on Friday, hitting $136.95. The company's stock had a trading volume of 1,666,195 shares, compared to its average volume of 771,482. Charles River Laboratories International, Inc. has a fifty-two week low of $132.99 and a fifty-two week high of $258.56. The business has a 50 day moving average price of $162.49 and a two-hundred day moving average price of $180.59. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The company has a market capitalization of $7.00 billion, a PE ratio of 912.99, a P/E/G ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to analysts' expectations of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm's revenue was down 1.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.46 earnings per share. As a group, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on CRL shares. Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their price target for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. Morgan Stanley dropped their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. Bank of America lowered their target price on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. Finally, William Blair cut Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. One research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $189.77.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).